• If you are wondering whether Amdocs stock is starting to look like value or a value trap, the current share price puts that question front and center.
• The stock closed at US$65.14 recently, with returns of 0.7% over 7 days, a 1.9% decline over 30 days, an 18.7% decline year to date and a 27.6% decline over the last year. This naturally raises questions about how the market is reassessing both growth potential and risk.
• Recent coverage has focused on how Amdocs fits into broader shifts in software and telecom IT spending, as large operators reassess their technology budgets and vendors. This context helps explain why investors are paying close attention to contract momentum and customer relationships, and how these factors might relate to the share price path.
• In this context, Amdocs currently holds a 5/6 valuation score, and the rest of this article will walk through the standard valuation checks before turning to a more nuanced way of thinking about the stock's value.

Approach 1: Amdocs Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today, using a required return to reflect risk and the time value of money.

For Amdocs, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow stands at about $758.0 million. Analysts supply cash flow projections for several years, and Simply Wall St extends these further. In this case, the ten year path for Free Cash Flow runs from $645.6 million in 2026, with a projected $956.5 million in 2030 and further extrapolated estimates out to 2035, all in dollar terms.

Bringing these projected cash flows back to today and aggregating them produces an estimated intrinsic value of about $140.05 per share. Compared with the recent share price of US$65.14, the DCF output implies the stock is about 53.5% undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Amdocs is undervalued by 53.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Amdocs Price vs Earnings

For a profitable company like Amdocs, the P/E ratio is a useful shorthand because it links what you pay directly to the earnings the business is already generating. Investors usually accept a higher P/E when they expect stronger earnings growth or see lower risk, and a lower P/E when they see more uncertainty or weaker growth prospects.

Amdocs currently trades on a P/E of 12.27x. That is close to the peer group average of 11.92x, but well below the broader IT industry average P/E of 21.39x. On the surface, the stock sits roughly in line with peers, yet it is priced at a discount to the wider sector.

Simply Wall St also calculates a proprietary “Fair Ratio” of 21.48x for Amdocs. This metric goes further than a simple peer or industry comparison because it incorporates factors such as earnings growth, profit margins, risk profile, industry characteristics and market capitalization. Compared with this Fair Ratio, Amdocs’ current P/E of 12.27x screens as materially lower, which points to the stock being undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Amdocs Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St let you turn your view of Amdocs into a clear story that links what the company is doing to a financial forecast and to an estimated fair value, all in one place on the Community page.

A Narrative starts with your assumptions for future revenue, earnings and margins, then ties those numbers to a fair value so you can quickly compare that figure with the current share price to help decide whether Amdocs looks interesting, fully priced or unattractive to you.

Because Narratives on Simply Wall St update automatically as new earnings, guidance or news come through, you are not locked into a static model and can see how your Amdocs view shifts in real time as information changes.

For Amdocs specifically, one investor might build a more optimistic Narrative that lines up with a fair value of about US$105.0, while another might prefer a more cautious Narrative closer to US$70.84. Seeing those different stories side by side highlights how reasonable people can look at the same stock and reach very different conclusions about value.

Do you think there's more to the story for Amdocs? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.